Clinical trial experience around the globe: Focus on calcium-channel blockers

Clinical Cardiology

Volumn 26, Issue 2 SUPPL., 2003, Pages

  White, William B ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium antagonists; Cardiovascular events; Clinical trials; Drug safety; Outcomes research

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; CHINA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; EUROPE; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; STROKE;

EID: 17344386430     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960261404     Document Type: Conference Paper

References (30)

1. Psaty BM, Heckbert SR, Koepsell TD: The risk of myocardial infarction associated with antihypertensive drug therapies. Jam Med Assoc 1995;274:620-625
2. Jick H, Derby LE, Guewich V, Vesilakis C: The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996;16:321-326
3. Pahor M, Guralnik JM, Salive ME: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-699
4. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. J Am Med Assoc 1997;277:739-745
5. Yusuf S. Held P. Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67:1295-1297
6. Pahor M, Psaty BM. Alderman MH: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 2000;356:1949-1954
7. Staessen JA, Fagard R, Thijs L, Celis H. Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW. Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764
8. Liu L, Wang JG, Gong L, Liu G, Staessen JA: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16:1823-1829
9. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW. Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-372
10. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000;356: 359-365
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF. Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
12. Kaplan NM: The CARE Study: A postmarketing evaluation of ramipril in 11, 100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996;18:658-670
13. Neal B. MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964
14. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001;358:1305-1315
15. Opie LH, Schall R: Evidence-based evaluation of calcium channel blockers for hypertension: Equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol 2002;39: 315-322
16. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652
17. Estacio RO, Schrier RW: Antihypertensive therapy in type 2 diabetes: Implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 1998;82:9R-14R
18. Schrier RW. Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002:61:1086-1097
19. Kannel WB. McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAm MedAssoc 1979;241:2035-2038
20. National Diabetes Data Group: Diabetes in America, 2nd ed. Bethesda, Md.: NIDDKD, 1996
21. Tuomilehto J, Rastenyte D. Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C. Fagard R: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340:677-684
22. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H. Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. J Am Med Assoc 1996:276:1886-1892
23. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991:265:3255-3264
24. Forette F, Amery A, Staessen J. Strasser T, Thijs L, Beevers DG, Bert P, Clement D, Cox J, de Leeuw PW: Is prevention of vascular dementia possible? The Syst-Eur Vascular Dementia Project. Aging Clin Exp Res (Milano) 1991;3:373-382
25. Seux ML, Thijs L, Forette F. Staessen JA, Birkenhager WH Bulpitt CJ, Girerd X, Jaaskivi M, Vanhanen H, Kivinen P. Yodfat Y, Vanska O, Antikainen R, Laks T, Webster JR, Hakamaki T, Lehtomaki E, Lilov E, Grigorov M, Janculova K, Halonen K, Kohonen-Jalonen P, Kermowa R, Nachev C, Tuomilehto J: Correlates of cognitive status of old patients with isolated systolic hypertension: The SystEur Vascular Dementia Project. J Hypertens 1998;16:963-969
26. Forette F, Seux ML, Staessen JA, Thijs L. Birkenhager WH, Babarskiene MR. Prevention of dementia in randomised double-blind placebo-controlled Systlic Hypertension (Syst-Eur) trial. Lancet 1998;352:1347-1351
27. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc 2000;283:1967-1975
28. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616
29. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-259
30. PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemia attack. Lancet 2001; 358:1033-1041